To Get Full Access :

Login with Linked
Login with Gmail

Follow us on

Link Linkedin Youtube

Itovebi

Itovebi is an oral targeted therapy, added to palbociclib and fulvestrant, for HR-positive, HER2-negative advanced breast cancer with PIK3CA mutations. It inhibits mutant PI3Kα to slow tumor progression and extend progression-free survival.

The information outlined in the molecule details section below would help you evaluate Para IV filing opportunities early to secure a first-to-file advantage.

Molecule Details :

  • Molecule Name :

    Inavolisib

  • Innovator :

    GENENTECH INC

  • Approval Date :

    10-Oct-24

  • NCE-1 Date :

    10-Oct-28

  • NCE Date :

    10-Oct-29

  • Dosage Form :

    Oral Tablets

  • Strength :

    3mg and 9mg

  • Therapeutic Category :

    Anticancer

  • Revenue ($M) :

    9

Year-wise Projected Sales ($M) :

  • 2025 :

    157

  • 2026 :

    396

  • 2027 :

    692

  • 2028 :

    990

  • 2029 :

    1,321

  • 2030 :

    1,626

  • 2031 :

    1,908
Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.
Request a Quote

Why Choose Spring Bio Solution?

Supported 1000+ Clinical Trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO Services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions 


Schedule a Call With Us
Login with Linked

Follow us on

Linkedin Youtube Link

Login With

For full access Sign-up / Sign-in using below Methods:

Linked
Gmail

By continuing, you agree to our Terms & Conditions and Privacy Policy. You can review them anytime.

Are you sure want to logout from NCE Grid?

Not Now
Logout
Need your comparator insight?